Ambrx Biopharma Inc (DELISTED) (AMAM:DL)
27.99
+0.01
(+0.04%)
USD |
NASDAQ |
Mar 06, 16:00
28.00
+0.01
(+0.04%)
After-Hours: 20:00
Ambrx Biopharma Cash from Financing (Quarterly): 9.71M for Sept. 30, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 9.71M |
| June 30, 2023 | 82.65M |
| March 31, 2023 | 77.22M |
| December 31, 2022 | -0.506M |
| Date | Value |
|---|---|
| September 30, 2022 | 1.468M |
| June 30, 2022 | -0.028M |
| March 31, 2022 | -0.006M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.506M
Minimum
Dec 2022
82.65M
Maximum
Jun 2023
24.36M
Average
1.468M
Median
Sep 2022
Cash from Financing (Quarterly) Benchmarks
| Johnson & Johnson | 546.00M |
| Axonics Inc | 0.248M |
| Harpoon Therapeutics Inc (DELISTED) | 2.032M |
| Merck & Co Inc | -2.814B |
| RayzeBio inc (DELISTED) | 314.84M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -18.88M |
| Cash from Investing (Quarterly) | 6.164M |
| Free Cash Flow | -58.82M |
| Free Cash Flow Per Share (Quarterly) | -0.308 |
| Free Cash Flow to Equity (Quarterly) | -19.18M |
| Free Cash Flow to Firm (Quarterly) | -19.18M |
| Free Cash Flow Yield | -0.81% |